SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRC SciSparc Ltd.

Market Closed 02-14 16:00:00 EST

0.4987

-0.0303

-5.73%

盘后0.4987

+0.00000.00%

19:34 EST

High0.5290	Low0.4805	Vol189.36K
Open0.5290	D1 Closing0.5290	Amplitude9.17%
Mkt Cap5.40M	Tradable Cap5.40M	Total Shares10.83M
T/O93.71K	T/O Rate1.75%	Tradable Shares10.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SPRC","market":"US","secType":"STK","nameCN":"SciSparc Ltd.","latestPrice":0.4987,"timestamp":1739566800000,"preClose":0.529,"halted":0,"volume":189355,"hourTrading":{"tag":"盘后","latestPrice":0.4987,"preClose":0.4987,"latestTime":"19:34 EST","volume":2198,"amount":1144.0114,"timestamp":1739579672655},"delay":0,"floatShares":10827900,"shares":10828300,"eps":-5.008752,"marketStatus":"Market Closed","change":-0.0303,"latestTime":"02-14 16:00:00 EST","open":0.529,"high":0.529,"low":0.4805,"amount":93709.07225575,"amplitude":0.091682,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-5.008752,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.529,"preHourTrading":{"tag":"盘前","latestPrice":0.504,"preClose":0.535,"latestTime":"08:44 EST","volume":103,"amount":52.711898000000005,"timestamp":1739540684231},"postHourTrading":{"tag":"盘后","latestPrice":0.4987,"preClose":0.4987,"latestTime":"19:34 EST","volume":2198,"amount":1144.0114,"timestamp":1739579672655},"volumeRatio":0.38138764651066615},"requestUrl":"/m/hq/s/SPRC","defaultTab":"news","newsList":[{"id":"2508548404","title":"Scisparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico","url":"https://stock-news.laohu8.com/highlight/detail?id=2508548404","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508548404?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:00","pubTimestamp":1738677602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nTUA25G9PL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","SPRC","CMND"],"gpt_icon":0},{"id":"2508454643","title":"SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico","url":"https://stock-news.laohu8.com/highlight/detail?id=2508454643","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508454643?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:00","pubTimestamp":1738677600,"startTime":"0","endTime":"0","summary":"The patent refers to SciSparc’s innovative combination therapy of N-Acylethanolamines and Clearmind’s MEAI,  addressing binge behaviour, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.This press release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looki","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-clearmind-collaboration-leads-publication-140000182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRC","BK4139","CMND","BK4007"],"gpt_icon":0},{"id":"2508451847","title":"Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico","url":"https://stock-news.laohu8.com/highlight/detail?id=2508451847","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508451847?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:35","pubTimestamp":1738676100,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, Feb. 04, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces today a patent publication by the Instituto Mexicano de la Propriedad Industrial , the National Mexico Patent Office. The patent refers to the Company’s innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.The Company’s intellectual portfolio ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-announces-publication-patent-133500310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRC","BK4139","BK4007","CMND"],"gpt_icon":0},{"id":"2504643198","title":"BUZZ-U.S. STOCKS ON THE MOVE-Bumble, Intel, Truist Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2504643198","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504643198?lang=en_us&edition=fundamental","pubTime":"2025-01-17 23:41","pubTimestamp":1737128464,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Bumble, Intel, Truist FinancialEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250117:nL4N3OD19A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HBAN","LU0957799991.USD","QRVO","LU0154245673.USD","INTC","LU0077335932.USD","CWAN","AMPX","LU0211328371.USD","X","GSK.UK","AMAT","LRCX","LU2023250843.SGD","STLD","RIVN","SLB","VST","BK4505","TFC","JBHT","LU0882574055.USD","LU0971552673.USD","SG9999002232.USD","WRBY","LU1880407132.USD","HUT","MYTE","LUCK","GSIT","SPRC","NUE","ORN","BMBL","BX","BK4515","LU0985489474.SGD","03165","LU0070302665.USD","FAST","BK4232","AZN.UK"],"gpt_icon":1},{"id":"2503629785","title":"SciSparc Gets 180-Day Nasdaq Extension to Regain Compliance With Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2503629785","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503629785?lang=en_us&edition=fundamental","pubTime":"2025-01-16 00:14","pubTimestamp":1736957679,"startTime":"0","endTime":"0","summary":"SciSparc  said Wednesday it received a Nasdaq notification letter stating that it was granted an additional 180-day compliance period, or until July 14, to regain compliance with the stock exchange's minimum bid price rule.The company said it didn't regain compliance with the minimum $1 bid price per share requirement during an initial 180-calendar-day compliance period and had filed a request to Nasdaq to get an additional 180-day extension.SciSparc said the latest Nasdaq notification has no immediate effect on the listing or trading of its shares.The company's shares were falling 1.5% in recent trading.Price: 0.75, Change: -0.01, Percent Change: -1.48","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QID","NDAQ","TSYW.SI","BK4585","LU2210149790.SGD","BK4112",".IXIC","NVIW.SI","IE00B64PRP62.GBP","NQmain","USJW.SI","BK4139","QLD","USAW.SI","TQQQ","IE00BKPKM429.USD","SQQQ","MNQmain","BK4007","SPRC","LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","PSQ","BK4588","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2503268648","title":"SciSparc granted 180-day extension to regain Nasdaq compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2503268648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503268648?lang=en_us&edition=fundamental","pubTime":"2025-01-15 20:42","pubTimestamp":1736944948,"startTime":"0","endTime":"0","summary":"SciSparc (SPRC)has received a notification letter from Nasdaq Stock Market that the Company has been granted an additional 180-day compliance perio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scisparc-granted-180-day-extension-to-regain-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scisparc-granted-180-day-extension-to-regain-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B64PRP62.GBP","TSYW.SI","USAW.SI","BK4585","IE00BKPKM429.USD",".IXIC","NVIW.SI","BK4007","LU2095319765.USD","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","NQmain","QID","SPRC","QLD","PSQ","IE00B3QW5Z07.USD","MNQmain","BK4588","BK4112","SQQQ","TQQQ","NDAQ","USJW.SI","LU2210150020.SGD"],"gpt_icon":0},{"id":"2503101286","title":"Scisparc Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2503101286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503101286?lang=en_us&edition=fundamental","pubTime":"2025-01-15 20:34","pubTimestamp":1736944449,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nFWN3OB02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRC","BK4139","BK4007"],"gpt_icon":0},{"id":"2503648952","title":"SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2503648952","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503648952?lang=en_us&edition=fundamental","pubTime":"2025-01-15 20:34","pubTimestamp":1736944440,"startTime":"0","endTime":"0","summary":"No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares. Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period and if necessary, by effecting a reverse share split.SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-granted-180-day-extension-123400993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","QID","BK4112","USJW.SI","IE00B3QW5Z07.USD","LU2210149790.SGD","SQQQ","BK4007","NDAQ","SPRC","IE00BGHQF748.EUR","BK4588","TSYW.SI","LU2095319765.USD","TQQQ","NQmain","NVIW.SI","IE00B64PRP62.GBP","QLD","IE00BKPKM429.USD",".IXIC","MNQmain","PSQ","LU2210150020.SGD","USAW.SI","BK4139"],"gpt_icon":1},{"id":"2503130054","title":"SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles","url":"https://stock-news.laohu8.com/highlight/detail?id=2503130054","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503130054?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:41","pubTimestamp":1736775660,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Jan. 13, 2025  -- SciSparc Ltd.  , announced that AutoMax Motors Ltd., , a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. , a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax’s direct import and distribution operations, launched under agreements signed earlier this year with JAC Motors.The shipment follows regulatory approvals for direct importation and positions AutoMax to begin marketing and sales activities for JAC Motors vehicles across Israel.JAC Motors has a strong focus on electric vehicles , making it a pioneer in sustainable transportation. The company has developed an impressive range of EVs, including passenger cars and commercial vehicles, supported by advanced R&D and cutting-edge battery technologies. AutoMax sees JAC's innovative EV ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-automax-enters-direct-import-134100920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","SPRC","BK4139"],"gpt_icon":1},{"id":"2501722664","title":"SciSparc says MitoCareX expands research to pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501722664","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501722664?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:30","pubTimestamp":1736339425,"startTime":"0","endTime":"0","summary":"SciSparc announced that MitoCareX Bio, its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following initial in-vitro results. MitoCareX recently achieved positive results using pancreatic cancer cell lines. These findings build on MitoCareX’s earlier success in developing a computationally advanced drug discovery platform that virtually screened millions of small molecules, identifying several as potential anti-cancer treatments. By leveraging its in-vitro screening systems related to mitochondria, MitoCareX corroborated the anti-cancer biological activity of several small molecule structures discovered out of millions of them that were virtually screened the addition of pancreatic cancer to its existing focus on non-small cell lung cancer marks a significant expansion of its therapeutic ambitions.Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/scisparc-says-mitocarex-expands-research-123025400.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-says-mitocarex-expands-research-123025400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","SPRC"],"gpt_icon":1},{"id":"2501081452","title":"Scisparc: Mitocarex Bio Expands Research to Pancreatic Cancer Following Initial in-Vitro Positive Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2501081452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501081452?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:25","pubTimestamp":1736252700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA1PH04H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRC","BK4007"],"gpt_icon":0},{"id":"2501208065","title":"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2501208065","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501208065?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:25","pubTimestamp":1736252700,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Jan. 07, 2025  -- SciSparc Ltd.  , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. , its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following encouraging initial in-vitro results.MitoCareX, which focuses on drug discovery and the development of cancer therapeutics targeting the mitochondrial SLC25 protein family, recently achieved positive results using pancreatic cancer cell lines. These findings build on MitoCareX’s earlier success in developing a computationally advanced drug discovery platform that virtually screened millions of small molecules, identifying several as potential anti-cancer treatments.By leveraging its in-vitro screening systems related to mitochondria, MitoCareX corroborated the anti-cancer biological activity of several small molecule structures di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-mitocarex-bio-expands-research-122500732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SPRC","BK4007"],"gpt_icon":1},{"id":"2501266173","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2501266173","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501266173?lang=en_us&edition=fundamental","pubTime":"2025-01-07 03:04","pubTimestamp":1736190277,"startTime":"0","endTime":"0","summary":"SciSparc (SPRC) announced the publication of a European patent application that its collaboration partner Clearmind Medicine (CMND) submitted with the European Patent Office for a binge behavior psych","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999015978.USD","LU0640476718.USD","BK4581","SG9999015986.USD","DIS","LU0708994859.HKD","LU0128525929.USD","SG9999015952.SGD","LU0061475181.USD","BK4534","LU1894683348.USD","GB00BDT5M118.USD","LU0310800379.SGD","BK4585","BK4524","LU0029864427.USD","POAI","LU0070302665.USD","BK4139","BK4561","BK4551","LU0786609619.USD","LU0011850046.USD","BK4550","BK4007","LU1267930573.SGD","SPRC","LU0208291251.USD","BK4108","LU1894683264.USD","BK4082","LU1280957306.USD","BK4198","RENB","BK4554","BK4598","BK4077","FUBO","SG9999015945.SGD","BK4532","BK4588","CMND","LU0320765489.SGD","BK4507"],"gpt_icon":1},{"id":"2501251442","title":"Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2501251442","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501251442?lang=en_us&edition=fundamental","pubTime":"2025-01-07 00:04","pubTimestamp":1736179490,"startTime":"0","endTime":"0","summary":"On Monday, SciSparc Ltd  stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro.SciSparc announced, as part of its ongoing collaboration with Clearmind Medicine Inc. , the publication of a European patent application submitted by Clearmind under the European Patent Office for combination therapy of MEAI and N-Acylethanolamines for binge behavior, including alcohol consumption, eating, tobacco consumption, shopping, and sexual conduct.To date, Clearmind has filed thirteen patents related to this collaboration in the United States and several other global jurisdictions.In September, the FDA approved SciSparc’s investigational new drug , which enables the company to proceed to Phase 2b trial for its medication to treatTourette Syndrome.Price Action: At the last check on Monday, SPRC stock was 152.90% at $1.39, and CMND stock was up 10.70% at $1.65.Commercial Metals Delivers Mixed Q1 Results As Economic Unc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-psychedelic-scisparc-stock-trading-160450282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CMND","SPRC","BK4139"],"gpt_icon":0},{"id":"2501237607","title":"Sector Update: Health Care Stocks Edge Higher Premarket Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2501237607","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501237607?lang=en_us&edition=fundamental","pubTime":"2025-01-06 22:11","pubTimestamp":1736172716,"startTime":"0","endTime":"0","summary":"Health care stocks were higher in Monday's premarket hours, with the Health Care Select Sector SPDR Fund  and the iShares Biotechnology ETF  each advancing by 0.3% recently.Regional Health Properties  and SunLink Health Systems  said they have agreed to merge in an all-stock deal. Regional Health shares soared more than 214% and SunLink Health shares were over 24% higher in recent premarket activity.SciSparc  announced the publication of a European patent application that its collaboration partner Clearmind Medicine  submitted with the European Patent Office for a binge behavior psychedelic combination treatment. Shares of SciSparc surged past 68% and Clearmind Medicine shares rose by over 6% pre-bell.CytoMed Therapeutics  shares were up over 20% after the company said it has signed a five-year business and research collaboration deal with SunAct Cancer Institute to explore the efficacy, potency, safety, and tolerability of CytoMed's proprietary allogeneic gamma delta T cells to treat ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","CMND","BK4007","BK4581","RHE","SSY","BK4185","SPRC","GDTC","XLV","IBB","BK4139"],"gpt_icon":1},{"id":"2501823239","title":"SciSparc Says Clearmind Medicine Files European Patent Application for Binge Behavior Psychedelic Combination Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2501823239","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501823239?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:49","pubTimestamp":1736171353,"startTime":"0","endTime":"0","summary":"SciSparc  announced Monday the publication of a European patent application that its collaboration partner Clearmind Medicine  submitted with the European Patent Office for a binge behavior psychedelic combination treatment.The companies are researching combination treatments that integrate psychedelic molecules with the N-acylethanolamines family, SciSparc said.Shares of SciSparc soared 188% and Clearmind Medicine rose 4% in premarket activity Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","CMND","SPRC"],"gpt_icon":1},{"id":"2501239533","title":"BRIEF-Scisparc-Clearmind Medicine Collaboration Announces The Publication Of European Patent Application For Binge Behavior Psychedelic Combination Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239533","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239533?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168404,"startTime":"0","endTime":"0","summary":"BRIEF-Scisparc-Clearmind Medicine Collaboration Announces The Publication Of European Patent Application For Binge Behavior Psychedelic Combination TreatmentJan 6  - Clearmind Medicine Inc CMND.O:SCISPARC-CLEARMIND MEDICINE COLLABORATION ANNOUNCES THE PUBLICATION OF EUROPEAN PATENT APPLICATION FOR BINGE BEHAVIOR PSYCHEDELIC COMBINATION TREATMENTSource text: nGNXc5537NFurther company coverage: CMND.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA8CV7JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4139","SPRC","BK4007"],"gpt_icon":1},{"id":"2501180236","title":"Scisparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2501180236","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501180236?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:50","pubTimestamp":1736167802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA8CV7JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRC","BK4007","BK4139","CMND"],"gpt_icon":0},{"id":"2501739239","title":"SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2501739239","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501739239?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:50","pubTimestamp":1736167800,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Jan. 06, 2025  -- SciSparc Ltd.  , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with Clearmind Medicine Inc.   , a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, the publication of a European patent application submitted by Clearmind under the European Patent Office for innovative combination therapy of MEAI and N-Acylethanolamines, to binge behavior including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and dev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-clearmind-medicine-collaboration-announces-125000550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SPRC","CMND","BK4007"],"gpt_icon":0},{"id":"2495615040","title":"SciSparc Gets Renewal From Israeli Medical Cannabis Agency for Autism Spectrum Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2495615040","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495615040?lang=en_us&edition=fundamental","pubTime":"2024-12-31 22:54","pubTimestamp":1735656870,"startTime":"0","endTime":"0","summary":"SciSparc  said Tuesday that the Israeli Medical Cannabis Agency at the Israeli Ministry of Health renewed an approval for the clinical trial of SCI-210 in children with autism spectrum disorder, or ASD.The 30-day approval is expected to be extended upon final Israeli police approval, expected within the same timeframe, SciSparc said.The SCI-210 clinical trial is a double-blind, randomized, placebo-controlled study at Soroka University Medical Center in Israel, involving 60 children aged 5 to18 with ASD, the pharmaceutical company said.The 20-week trial will evaluate the efficacy and safety of SCI-210, which is a combination of a proprietary cannabidiol, or CBD, and CannAmide, against standard CBD therapy. The trial will focus on symptom management and therapeutic outcomes, SciSparc said, adding that it aims to launch SCI-210 in Israel first, with plans for international expansion pending regulatory approvals.Price: 0.44, Change: -0.02, Percent Change: -4.98","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACB","BK4139","SPRC","BK4007","BK4018","BK4557","SPB","LU2065732104.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.scisparc.com","stockEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":-0.3397},{"period":"3month","weight":1.1998},{"period":"6month","weight":0.3478},{"period":"1year","weight":-0.8591},{"period":"ytd","weight":0.3853}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01448},{"month":2,"riseRate":0.5,"avgChangeRate":-0.036021},{"month":3,"riseRate":0,"avgChangeRate":-0.370645},{"month":4,"riseRate":0.333333,"avgChangeRate":0.026788},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.101764},{"month":6,"riseRate":0,"avgChangeRate":-0.205264},{"month":7,"riseRate":0,"avgChangeRate":-0.28376},{"month":8,"riseRate":0,"avgChangeRate":-0.43328},{"month":9,"riseRate":0,"avgChangeRate":-0.169119},{"month":10,"riseRate":1,"avgChangeRate":0.257399},{"month":11,"riseRate":0.666667,"avgChangeRate":0.118265},{"month":12,"riseRate":0.333333,"avgChangeRate":0.005952}],"exchange":"NASDAQ","name":"SciSparc Ltd.","nameEN":"SciSparc Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SciSparc Ltd.(SPRC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SciSparc Ltd.,SPRC,SciSparc Ltd.股票,SciSparc Ltd.股票老虎,SciSparc Ltd.股票老虎国际,SciSparc Ltd.行情,SciSparc Ltd.股票行情,SciSparc Ltd.股价,SciSparc Ltd.股市,SciSparc Ltd.股票价格,SciSparc Ltd.股票交易,SciSparc Ltd.股票购买,SciSparc Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SciSparc Ltd.(SPRC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}